Renal Disease, Homocysteine, and Cardiovascular Complications

Circulation

Volumn 109, Issue 3, 2004, Pages 294-295

  Robinson, Killian ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular diseases; Focused Perspectives; Kidney

Indexed keywords

ACETYLCYSTEINE; CONTRAST MEDIUM; FOLIC ACID; HOMOCYSTEINE; SULFUR AMINO ACID;

AMINO ACID BLOOD LEVEL; ANTIOXIDANT ACTIVITY; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CONTRAST RADIOGRAPHY; DRUG INTOXICATION; HEMODIALYSIS; HUMAN; KIDNEY DISEASE; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VOMITING;

ACETYLCYSTEINE; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; HOMOCYSTEINE; HUMANS; KIDNEY FAILURE, CHRONIC; RISK FACTORS;

EID: 1642458143     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000114133.99074.96     Document Type: Review

References (20)

1. United States Renal Data System. Available at: http://www.usrds.org/2003/pdf/06_hosp_morte_03.pdf. Accessed December 19, 2003.
2. Henry RM, Kostense PJ, Bos G, et al. Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn Study. Kidney Int. 2002;62:1402-1407.
3. Kronenberg F, Kuen E, Ritz E, et al. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol. 2000;11:105-115.
4. Kielstein JT, Boger RH, Bode-Boger SM, et al. Marked increase of asymmetric dimethyl arginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol. 2002;13:170-176.
5. Wilcken DEL, Gupta VJ, Reddy SG. Accumulation of sulphur-containing amino acids including cysteine-homocysteine in patients on maintenance haemodialysis. Clin Sci. 1980;58:427-430.
6. Moustapha A, Naso A, Nahlawi M, et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end stage renal disease. Circulation. 1998;97:138-141.
7. Perna AF, Ingrosso D, Lombardi C, et al. Possible mechanisms of homocysteine toxicity. Kidney Int Suppl. 2003;63:S137-S140.
8. Massy ZA. Potential strategies to normalize the levels of homocysteine in chronic renal failure patients. Kidney Int Suppl. 2003;63:S134-S136.
9. Friedman AN, Bostom AG, Levey AS, et al. Plasma total homocysteine levels among patients undergoing nocturnal versus standard hemodialysis. J Am Soc Nephrol. 2002;13:265-268.
10. Scholze A, Rinder C, Beige J, et al. Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation. 2004;109:369-374.
11. Sochman J. N-Acetylcysteine in acute cardiology: 10 years later: what do we know and what would we like to know?! J Am Coll Cardiol. 2002;39:1422-1428.
12. Andrews NP, Prasad A, Quyyumi AA. N-acetylcysteine improves coronary and peripheral vascular function. J Am Coll Cardiol. 2001;37:117-123.
13. Birck R, Krzossok S, Markowetz F, et al. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet. 2003;362:598-603.
14. Friedman AN, Bostom AG, Laliberty P, et al. The effect of N-acetylcysteine on plasma total homocysteine levels in hemodialysis: a randomized, controlled study. Am J Kidney Dis. 2003;41:442-446.
15. Schnyder G, Roffi M, Pin R, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med. 2001;345:1593-1600.
16. Schnyder G, Roffi M, Flammer Y, et al. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. JAMA. 2002;288:973-979.
17. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, et al. Secondary prevention with folic acid: effects on clinical outcomes. J Am Coll Cardiol. 2003;41:2105-2113.
18. Verhaar MC, Stroes E, Rabelink TJ. Folates and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2002;22:6-13.
19. National Institute of Diabetes and Digestive and Kidney Diseases. The Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT). Available at: http://www.niddk.nih.gov/patient/favorit/favorit.htm. Accessed December 19, 2003.
20. Tepel M, van der Giet M, Statz M, et al. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation. 2003;107:992-995.